Abstract
BackgroundAs the most ordinary metabolic disorder during pregnancy, gestational diabetes mellitus (GDM) has become a severe risk for the health of both pregnant female and fetus. Astragaloside IV (AS-IV) is the dominant active component in Astragalus membranaceus. It has been proved that AS-IV has anti-inflammation and immune-regulation function. We aimed to demonstrate the function of AS-IV in the therapy of GDM and the molecular mechanism in this process.MethodsC57BL/KsJ-Lepdb/+ female mice were used as GDM model. The mRNA levels of relative genes in this research were detected by qRT-PCR. The protein levels of relative genes were analyzed by western blot. Serum concentration of interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α) were analyzed by ELISA.ResultsGlucose and insulin levels in GDM mice model were decreased by AS-IV treatment. AS-IV down-regulated the expression of inflammatory gene IL-6 and TNF-α in GDM mice model. AS-IV treatment inhibited the expression of NLR family pyrin domain containing-3 (NLRP3) inflammasome relative proteins in the pancreas of GDM mice.ConclusionThis study demonstrated that AS-IV treatment has an effective therapeutic function of GDM in mice model through the inhibition of NLRP3 inflammasome in the pancreas.
Highlights
As the most ordinary metabolic disorder during pregnancy, gestational diabetes mellitus (GDM) has become a severe risk for the health of both pregnant female and fetus
Astragaloside IV (AS-IV) attenuated GDM symptoms in pregnant db/+ mice We first examined the effect of AS-IV treatment on the GDM symptoms in pregnant db/+ mice
These data proved that AS-IV played a role in the improvement of reproductive outcome in GDM mice model
Summary
As the most ordinary metabolic disorder during pregnancy, gestational diabetes mellitus (GDM) has become a severe risk for the health of both pregnant female and fetus. Astragaloside IV (AS-IV) is the dominant active component in Astragalus membranaceus. In a part of pregnant women, diabetes is promoted by pregnancy related hyperinsulinemia and insulin resistance (IR) [1]. Gestational diabetes mellitus (GDM) is a metabolic disorder in pregnant female which is characterized by the glucose intolerance during the second or third trimester of pregnancy [2]. The adverse outcomes caused by the pathogenesis of GDM includes insulin resistance, hyperinsulinemia, hyperglycemia, and abnormal embryo development [3]. Among the extraction of Astragalus membranaceus, Astragaloside IV (AS-IV) is the dominant active component [12]. As a consequence of its antiinflammation function, AS-IV may play a role in the therapy of GDM
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
